Georgia-based EarliTec Diagnostics specializes in developing tools and devices for the detection of Autism Spectrum Disorder (ASD) and related disabilities. Its proprietary diagnostic tool measures a child’s preferential attention to social information based on their eye movement, supporting early detection of ASD. A child is shown a series of short videos showing social interaction, while the firm's eye-tracking technology monitors focus and responsiveness. This data is then compared to age-expected reference metrics to determine potential developmental conditions.
In June 2022, the company received FDA 510(k) approval for ‘EarliPoint Evaluation’, a device used for the diagnosis and assessment of ASD among children between the ages of 16 and 30 months. The firm plans to continue clinical research and expand partnerships within the ASD community.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.